Shares of pharmaceutical company Vertex Pharmaceuticals were falling this week after the company announced that it was going to stop testing on a drug designed to treat protein deficiencies. Based on early data of its Phase II trial of VX-814 in Alpha-1 antitrypsin deficiency (AATD), the company is halting the trial and ending development of … Continue reading “Vertex Shares Drop After Company Stops Testing on Protein Deficiency Treatment”
